menu
    • menu
    [{"orgOrder":0,"company":"Pleco Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NETHERLANDS","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"PTX-252","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Pleco Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Pleco Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Pleco Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Pleco Therapeutics","sponsor":"Oost NL","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"NETHERLANDS","productType":"Other Small Molecule","year":"2022","type":"Series A Financing","leadProduct":"PTX-061","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Pleco Therapeutics","amount2":0.02,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0.02,"dosageForm":"Injection","sponsorNew":"Pleco Therapeutics \/ Oost NL","highestDevelopmentStatusID":"4","companyTruncated":"Pleco Therapeutics \/ Oost NL"},{"orgOrder":0,"company":"Pleco Therapeutics","sponsor":"Hyloris Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"BELGIUM","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"PTX-252","moa":"Undisclosed","graph1":"Oncology","graph2":"Undisclosed","graph3":"Pleco Therapeutics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Pleco Therapeutics \/ Pleco Therapeutics","highestDevelopmentStatusID":"1","companyTruncated":"Pleco Therapeutics \/ Pleco Therapeutics"},{"orgOrder":0,"company":"Pleco Therapeutics","sponsor":"Hyloris Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"BELGIUM","productType":"Other Small Molecule","year":"2021","type":"Partnership","leadProduct":"Plecoid","moa":"Undisclosed","graph1":"Oncology","graph2":"Undisclosed","graph3":"Pleco Therapeutics","amount2":0.01,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0.01,"dosageForm":"Undisclosed","sponsorNew":"Pleco Therapeutics \/ Pleco Therapeutics","highestDevelopmentStatusID":"1","companyTruncated":"Pleco Therapeutics \/ Pleco Therapeutics"}]

    Find Clinical Drug Pipeline Developments & Deals by Pleco Therapeutics

    Menu

    Pleco Therapeutics

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Pleco Therapeutics

                            Netherlands arrow
                            ESCRS
                            Not Confirmed

                            Pleco Therapeutics

                            Netherlands arrow
                            ESCRS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : PTX-252

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Pleco Announces Positive FDA Pre-IND Outcome for PTX-252 in AML

                            Details : PTX-252 (previously referenced as a Plecoid™Agent) is a novel molecular entity. It is under clinical development for the treatment of Acute Myeloid Leukaemia (AML).

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            March 26, 2025

                            Lead Product(s) : PTX-252

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Pleco Therapeutics

                            Netherlands arrow
                            ESCRS
                            Not Confirmed

                            Pleco Therapeutics

                            Netherlands arrow
                            ESCRS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : PTX-252

                            Therapeutic Area : Oncology

                            Study Phase : Undisclosed

                            Recipient : Hyloris Pharmaceuticals

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            U.S. FDA Grants Orphan Drug Designation to PTX-252 for Treating Acute Myeloid Leukemia

                            Details : PTX-252 (previously referenced as a Plecoid™Agent) is a novel molecular entity. It is under clinical development for the treatment of cute Myeloid Leukaemia (AML).

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            January 16, 2024

                            Lead Product(s) : PTX-252

                            Therapeutic Area : Oncology

                            Highest Development Status : Undisclosed

                            Recipient : Hyloris Pharmaceuticals

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Pleco Therapeutics

                            Netherlands arrow
                            ESCRS
                            Not Confirmed

                            Pleco Therapeutics

                            Netherlands arrow
                            ESCRS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : PTX-061

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : Oost NL

                            Deal Size : $17.4 million

                            Deal Type : Series A Financing

                            DEALS_DEV arrow-down

                            Pleco Therapeutics Announces Final Close of its Series A Financing Raising €17.3m to Progress its Novel Plec...

                            Details : The funds will be used to complete development and commercialise the Company’s novel lead Plecoid™ Product, PTX-061, to improve the effectiveness of chemotherapy in patients with Acute Myeloid Leukaemia (AML).

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            June 09, 2022

                            Lead Product(s) : PTX-061

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : Oost NL

                            Deal Size : $17.4 million

                            Deal Type : Series A Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Pleco Therapeutics

                            Netherlands arrow
                            ESCRS
                            Not Confirmed

                            Pleco Therapeutics

                            Netherlands arrow
                            ESCRS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Plecoid

                            Therapeutic Area : Oncology

                            Study Phase : Undisclosed

                            Recipient : Hyloris Pharmaceuticals

                            Deal Size : $9.8 million

                            Deal Type : Partnership

                            DEALS_DEV arrow-down

                            Hyloris Broadens Pipeline with Novel Patented Combination Product Candidate in Acute Myeloid Leukaemia and Sma...

                            Details : The Plecoid FDC product is a patented, innovative, clinical-stage candidate drug that combines chelating agents with different characteristics. Previous studies demonstrate that elevated levels of toxic metals are associated with inferior survival in pat...

                            Product Name : Plecoid

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            October 11, 2021

                            Lead Product(s) : Plecoid

                            Therapeutic Area : Oncology

                            Highest Development Status : Undisclosed

                            Recipient : Hyloris Pharmaceuticals

                            Deal Size : $9.8 million

                            Deal Type : Partnership

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth